Market Closed - Euronext Paris 11:35:21 2024-04-26 am EDT 5-day change 1st Jan Change
2.02 EUR +0.50% Intraday chart for Crossject -1.94% -59.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CROSSJECT : Patience is a virtue… hopefully AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CROSSJECT : Invest Securities slightly reduces its target CF
CROSSJECT : Securing the financing needs AL
Crossject: share price falls after convertible bond issue CF
Crossject Société Anonyme announced that it expects to receive ?12 million in funding CI
CROSSJECT : No news is not always good news... AL
Crossject: strategy advances, but visibility worries CF
CROSSJECT : Marketing initiative in the US AL
Crossject: Syneos Health hired for Zepizure in the USA CF
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment MT
CROSSJECT : A new distribution agreement in Northern Europe AL
France's Crossject Inks New Commercialization Deal for Epileptic Seizure Therapy in Northern EU MT
Crossject: commercial agreement in Northern Europe CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe CI
CROSSJECT : H1 23: no surprises before the release of the detailed accounts in October AL
Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Crossject: improved ESG rating in the Gaïa ranking CF
Crossject: manufacturing audits passed CF
Crossject Completes European, US Audits for Manufacturing of Seizure Medication for US MT
AFT Pharmaceuticals Secures Australia, New Zealand License for Epilepsy Rescue Medication MT
Crossject Société Anonyme Signs New Licensing Agreement on Zeno Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand CI
Crossject: appointment to the Supervisory Board CF
CROSSJECT : No real news in the FY22 results. AL
CROSSJECT : FY22: not much to learn from the release AL
Chart Crossject
More charts
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.02 EUR
Average target price
5 EUR
Spread / Average Target
+147.52%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ALCJ Stock
  4. News Crossject
  5. Crossject Completes European, US Audits for Manufacturing of Seizure Medication for US